What are the clinical benefits and potential disadvantages of switching from fedratinib to momelotinib in the management of myelofibrosis?

Read full text Summarise with VIRAT
Authors: Tripdatabase
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Switching from fedratinib to momelotinib in myelofibrosis management may enhance anemia control and symptom relief, though it carries potential disadvantages such as side effects and cost. Direct comparisons between these drugs are needed to better understand their relative benefits and risks.

Fields of Study & Subjects

Myeloproliferative Neoplasms: Diagnosis and Treatment Chronic Lymphocytic Leukemia Research Acute Myeloid Leukemia Research

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
26 March 2026
Language
EN